Nov. 3, 2011
/PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), a medical device company that designs, manufactures, and markets innovative therapeutic ultrasonic products worldwide for wound debridement, spinal surgery, cosmetic surgery, neurosurgery, laparoscopic surgery and other surgical applications, announced its recent attendance at the 8th Annual "Wild on Wounds" Conference, sponsored by the Wound Care Education Institute ("WCEI"), which was held in
Las Vegas, NV
during September, 2011. The Company exhibited and demonstrated its SonicOne® Ultrasonic Wound Cleansing and Debridement System to many of the approximately 675 clinicians in attendance.
WCEI is the wound care industry's leading education provider. Their mission is to develop multi-disciplinary wound care professionals in
the United States
by offering educational programs and clinical support based on up to date wound care research, trends, and evidence based practice.
The SonicOne is an innovative wound care system designed to help address the challenges chronic wounds present to the patient, the healthcare professional and the healthcare system. The SonicOne System establishes a new standard in wound bed preparation, an essential first step in the wound healing process.
"Once again, Misonix was able to demonstrate its commitment to the rapidly growing wound care market by supporting important educational programs like WCEI's 'Wild on Wounds Conference,'" said
Michael A. McManus, Jr.
, President and Chief Executive Officer of Misonix. "We believe our wound care platform can make an important contribution to improving patient outcomes and we are always gratified when we can demonstrate our technology to clinicians."
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of
annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.